National Comprehensive Cancer Network

About The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Development and Update of the NCCN Guidelines
Recent Updates to NCCN Guidelines®
NCCN Guidelines Panels-Meeting Schedule
NCCN Categories of Evidence and Consensus
NCCN Categories of Preference
NCCN Guidelines® Steering Committee
Transparency: Process and Recommendations
Submission Request to the NCCN Guidelines Panels
Submission Request History
NCCN Compendium®
About the NCCN Compendium®
NCCN Compendium® Chapters By Disease
Subscribe to the NCCN Compendium
No Longer Recommended Uses
NCCN Framework for Resource Stratification of NCCN Guidelines
(NCCN Framework™)

NCCN Guidelines® & Clinical Resources

NCCN Drugs & Biologics Compendium (NCCN Compendium®)

You must Login or Register to access this information.

Based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®) contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer.

The recommendations for appropriate use of drugs and biologics contained in the NCCN Compendium® are extracted directly from the relevant NCCN Guidelines® along with their clinical context, route of administration, recommended use, and NCCN category of evidence. NCCN staff pharmacists generate the NCCN Compendium at the agent level rather than regimen; however, these agents reflect the components of regimens used in disease management. In addition to Guidelines specific indication and use, NCCN adds relevant information such as pharmacologic class, relevant ICD-9 and ICD-10 codes, and FDA indication to the searchable database. Compendium development and maintenance is accomplished by disease site and reviewed by members of the relevant NCCN panel before publication.

The NCCN Compendium® is recognized by public and private insurers alike, including, but not limited to the Centers for Medicare and Medicaid Services (CMS) and UnitedHealthcare as an authoritative reference for oncology coverage policy. Managed care medical directors, pharmacy benefits directors, and other health care professionals also reference the NCCN Compendium when making decisions that impact patient access to appropriate therapy. The uses identified are based upon evaluation of evidence from scientific literature integrated with expert judgment in an evidence-based process. Indicated uses are categorized in a systematic approach that describes the type of evidence available for and the degree of consensus underlying each recommendation. All recommendations (at all category levels) in the NCCN Compendium constitute appropriate, medically-necessary care. The NCCN Compendium lists both FDA-approved uses and appropriate uses beyond the FDA-approved label.

The NCCN Drugs & Biologics Compendium (NCCN Compendium®) is copyrighted by the NCCN. All rights reserved. NCCN content may not be reproduced in any form for any purpose without the express written permission of the NCCN. Permissions Requests Section

Table of Contents

Browse by Generic Name:
A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z

Search by Generic name: Search

You must Login or Register to access this information.

  • Abiraterone acetate
  • Acitretin
  • Ado-trastuzumab emtansine
  • Afatinib
  • Aldesleukin; Interleukin-2, recombinant
  • Alectinib
  • Alemtuzumab
  • Alendronate sodium
  • Alprazolam
  • Alteplase
  • Altretamine
  • Aminolevulinic acid hydrochloride
  • Anagrelide
  • Anakinra
  • Anastrozole
  • Antithymocyte globulin, equine
  • Apixaban
  • Aprepitant
  • Argatroban
  • Arsenic trioxide
  • Asparaginase Erwinia chrysanthemi
  • Aspirin
  • Atezolizumab
  • Avelumab
  • Axitinib
  • Azacitidine
Back to Top
  • BCG Live (Bacillus Calmette-Guerin)
  • Belinostat
  • Bendamustine hydrochloride
  • Benztropine mesylate
  • Bevacizumab
  • Bexarotene
  • Bexarotene Gel
  • Bicalutamide
  • Bivalirudin
  • Bleomycin sulfate
  • Blinatumomab
  • Bortezomib
  • Bosutinib
  • Brentuximab vedotin
  • Brigatinib
Back to Top
  • Cabazitaxel
  • Cabozantinib
  • Capecitabine
  • Carboplatin
  • Carfilzomib
  • Carmustine
  • Carmustine Implant
  • Celecoxib
  • Ceritinib
  • Cetuximab
  • Chlorambucil
  • Cisplatin
  • Cladribine
  • Clofarabine
  • Cobimetinib
  • Crizotinib
  • Cyclophosphamide
  • Cyclosporine
  • Cytarabine
  • Cytarabine injection, lipid complex
Back to Top
  • Dabigatran
  • Dabrafenib
  • Dacarbazine
  • Dactinomycin
  • Dalteparin sodium
  • Danazol
  • Daratumumab
  • Darbepoetin alfa
  • Dasatinib
  • Daunorubicin hydrochloride
  • Decitabine
  • Degarelix
  • Denosumab
  • Dexamethasone; Dexamethasone sodium phosphate
  • Diazoxide
  • Diclofenac sodium
  • Diphenhydramine hydrochloride
  • Docetaxel
  • Dolasetron mesylate
  • Doxazosin mesylate
  • Doxorubicin hydrochloride
  • Doxorubicin hydrochloride, Liposome injection
  • Doxycycline
  • Dronabinol
  • Durvalumab
Back to Top
  • Edoxaban
  • Elotuzumab
  • Eltrombopag
  • Enoxaparin sodium
  • Enzalutamide
  • Epirubicin hydrochloride
  • Eplerenone
  • Epoetin alfa
  • Eribulin
  • Erlotinib hydrochloride
  • Ethinyl estradiol
  • Etoposide; Etoposide phosphate
  • Everolimus
  • Exemestane
Back to Top
  • Ferric carboxymaltose
  • Filgrastim
  • Filgrastim-sndz
  • Floxuridine
  • Fludarabine phosphate
  • Fluorouracil
  • Fluoxymesterone
  • Flutamide
  • Fondaparinux sodium
  • Fosaprepitant dimeglumine
  • Fulvestrant
Back to Top
  • Ganciclovir sodium
  • Gefitinib
  • Gemcitabine hydrochloride
  • Goserelin acetate
  • Granisetron hydrochloride
  • Granisetron hydrochloride; Granisetron Transdermal System
  • Granisetron hydrochloride; Granisetron Transdermal System; Granisetron extended release subcutaneous injection
  • Granisetron Transdermal System
Back to Top
  • Haloperidol; Haloperidol lactate
  • Heparin sodium
  • Histrelin acetate
  • Hydrocortisone
  • Hydrocortisone sodium succinate
  • Hydroxyurea
Back to Top
  • Ibritumomab tiuxetan
  • Ibrutinib
  • Idarubicin hydrochloride
  • Idarucizumab
  • Idelalisib
  • Ifosfamide
  • Imatinib mesylate
  • Imiquimod
  • Ingenol mebutate
  • Inotuzumab ozogamicin
  • Interferon alfa-2b, recombinant
  • Interferon gamma-1B
  • Ipilimumab
  • Irinotecan hydrochloride
  • Irinotecan liposome injection
  • Iron dextran injection, low molecular weight
  • Iron sucrose injection
  • Isotretinoin (13-cis-retinoic acid)
  • Ixabepilone
  • Ixazomib
Back to Top
Back to Top
  • Ketoconazole
Back to Top
  • Lanreotide
  • Lapatinib
  • Lenalidomide
  • Lenvatinib
  • Letrozole
  • Leucovorin calcium
  • Leuprolide acetate
  • Leuprolide acetate for depot suspension
  • Levoleucovorin
  • Levonorgestrel
  • Levothyroxine sodium
  • Lomustine
  • Lorazepam
Back to Top
  • Mechlorethamine hydrochloride
  • Medroxyprogesterone acetate
  • Megestrol acetate
  • Melphalan; Melphalan hydrochloride
  • Mercaptopurine
  • Mesna
  • Methotrexate; Methotrexate sodium
  • Methoxsalen
  • Methylprednisolone acetate; Methylprednisolone sodium succinate
  • Methyltyrosine
  • Metoclopramide hydrochloride
  • Midostaurin
  • Mifepristone
  • Mitomycin; Mitomycin C
  • Mitotane
  • Mitoxantrone hydrochloride
Back to Top
  • Nabilone
  • Nelarabine
  • Netupitant/Palonosetron
  • Nicotinamide
  • Nilotinib hydrochloride monohydrate
  • Nilutamide
  • Niraparib
  • Nivolumab
Back to Top
  • Obinutuzumab
  • Octreotide acetate
  • Octreotide acetate (LAR)
  • Ofatumumab
  • Olanzapine
  • Olaparib
  • Olaratumab
  • Omacetaxine
  • Ondansetron hydrochloride
  • Osimertinib
  • Oxaliplatin
Back to Top
  • Paclitaxel
  • Paclitaxel, albumin bound
  • Palbociclib
  • Palonosetron hydrochloride
  • Pamidronate disodium
  • Panitumumab
  • Panobinostat
  • Pazopanib
  • Pegaspargase
  • Pegfilgrastim
  • Peginterferon alfa-2a
  • Peginterferon alfa-2b
  • Pembrolizumab
  • Pemetrexed
  • Pentostatin
  • Pertuzumab
  • Phenoxybenzamine hydrochloride
  • Phentolamine mesylate
  • Phytonadione (vitamin K1)
  • Plerixafor
  • Pomalidomide
  • Ponatinib
  • Porfimer sodium
  • Pralatrexate
  • Prazosin hydrochloride
  • Prednisolone
  • Prednisone
  • Procarbazine hydrochloride
  • Prochlorperazine edisylate, Prochlorperazine maleate
  • Prochlorperazine maleate
  • Promethazine hydrochloride
  • Protamine sulfate
Back to Top
Back to Top
  • Raloxifene hydrochloride
  • Ramucirumab
  • Regorafenib
  • Reteplase
  • Ribociclib
  • Rituximab
  • Rituximab and hyaluronidase human
  • Rivaroxaban
  • Rolapitant
  • Romidepsin
  • Romiplostim
  • Rucaparib
  • Ruxolitinib
Back to Top
  • Sargramostim
  • Scopolamine, transdermal
  • Siltuximab
  • Sipuleucel-T
  • Sirolimus
  • Sodium ferric gluconate complex in sucrose injection
  • Sonidegib
  • Sorafenib tosylate
  • Spironolactone
  • Streptozocin
  • Sulindac
  • Sunitinib malate
Back to Top
  • Talimogene laherparepvec
  • Tamoxifen citrate
  • Tazarotene
  • Tbo-filgrastim
  • Telotristat ethyl
  • Temozolomide
  • Temsirolimus
  • Tenecteplase
  • Terazosin hydrochloride
  • Thalidomide
  • Thiotepa
  • Tisagenlecleucel
  • Tocilizumab
  • Topotecan; Topotecan hydrochloride
  • Toremifene citrate
  • Trabectedin
  • Trametinib
  • Trastuzumab
  • Tretinoin (ATRA)
  • Trifluridine/Tipiracil
  • Triptorelin pamoate
Back to Top
Back to Top
  • Valganciclovir hydrochloride
  • Valrubicin
  • Vandetanib
  • Vemurafenib
  • Venetoclax
  • Vinblastine sulfate
  • Vincristine sulfate
  • Vincristine sulfate, liposome injection
  • Vinorelbine tartrate
  • Vismodegib
  • Vorinostat
Back to Top
  • Warfarin sodium
Back to Top
Back to Top
Back to Top
  • Zidovudine
  • Ziv-aflibercept
  • Zoledronic acid
Back to Top


The NCCN Guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to cancer treatment. The recommendations regarding the uses and indications in the NCCN Compendium have been derived directly from the NCCN Guidelines. The NCCN Compendium represents neither an all-inclusive listing of every drug and biologic nor every appropriate use and indication for drugs and biologics. The NCCN Templates are peer reviewed statements of consensus of their authors derived from the NCCN Guidelines for the conditions the NCCN Templates address. The NCCN Templates are not exhaustive and do not represent the full spectrum of care or treatment options described in the NCCN Guidelines or the NCCN Compendium or include all appropriate approaches or combinations of drugs or biologics for the treatment of cancer. A NCCN Template does not constitute an order.